Mary Fidler, MD
Medical Oncology · Chicago, ILNPI 1598960494
Payments from drug & device makers
Across 414 payments — averaging $5009.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$858K
- Merck$662K
- Genentech, Inc.$132K
- Alkermes, Inc.$80K
- Halozyme Inc$58K
- Gilead$41K
- plus $242K from 28 others
Across 6 payments — averaging $558.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3K
- F. Hoffmann-la Roche AG$810
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 112 | $857,939 |
| Merck | 67 | $662,326 |
| Genentech, Inc. | 28 | $132,347 |
| Alkermes, Inc. | 18 | $80,002 |
| Halozyme Inc | 13 | $58,272 |
| Gilead | 10 | $41,334 |
| Amgen | 4 | $33,246 |
| Pfizer | 3 | $29,444 |
| Iovance Biotherapeutics, Inc. | 16 | $27,005 |
| Novocure Inc. | 25 | $26,074 |
| Astrazeneca UK Limited | 21 | $22,044 |
| EMD Serono, Inc. | 6 | $13,897 |
| Genentech USA, Inc. | 12 | $10,918 |
| Novartis | 8 | $9,946 |
| Daiichi Sankyo Inc. | 22 | $9,866 |
| Lilly USA, LLC | 3 | $7,600 |
| Jazz Pharmaceuticals Inc. | 5 | $7,448 |
| E.r. Squibb & Sons, L.L.C. | 7 | $6,919 |
| Boehringer Ingelheim | 3 | $5,180 |
| AbbVie | 5 | $5,055 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $4,140 |
| Regeneron Healthcare Solutions, Inc. | 5 | $3,886 |
| Regeneron | 1 | $3,168 |
| Sanofi | 1 | $2,884 |
| Beigene USA, Inc. | 1 | $2,600 |
| Bristol Myers Squibb(2 entities) | 4 | $2,338 |
| Johnson & Johnson | 3 | $1,898 |
| Beigene, Ltd. | 1 | $1,809 |
| Janssen Scientific Affairs, LLC | 1 | $1,768 |
| G1 Therapeutics, Inc. | 1 | $1,500 |
| Eli Lilly | 1 | $800 |
| Coherus Oncology, Inc. | 3 | $349 |
| Puma Biotechnology, Inc. | 1 | $41 |
| Tempus AI, Inc | 1 | $14 |
How this compares
$2,074,055 in reported general payments places this provider in the 90th percentile of 144 medical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Chicago
- Andrzej JakubowiakChicago$42M
- Alexander PearsonChicago$9.3M
- Jyoti PatelChicago$7.5M
- Devalingam MahalingamChicago$7.1M
- Ardaman ShergillChicago$4.9M
- Sunandana ChandraChicago$4.6M
- William GradisharChicago$3.3M
- Manali BhaveChicago$3.3M
- Eugene AhnChicago$2.8M
- Nisha MohindraChicago$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.